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We conducted a phase II trial to evaluate the efficacy and toxicity of radiotherapy immediately after hyperbaric oxygenation (HBO)
with chemotherapy in adults with high-grade gliomas. Patients with histologically confirmed high-grade gliomas were administered
radiotherapy in daily 2Gy fractions for 5 consecutive days per week up to a total dose of 60Gy. Each fraction was administered
immediately after HBO with the period of time from completion of decompression to irradiation being less than 15min.
Chemotherapy consisted of procarbazine, nimustine (ACNU) and vincristine and was administered during and after radiotherapy. A
total of 41 patients (31 patients with glioblastoma and 10 patients with grade 3 gliomas) were enrolled. All 41 patients were able to
complete a total radiotherapy dose of 60Gy immediately after HBO with one course of concurrent chemotherapy. Of 30 assessable
patients, 17 (57%) had an objective response including four CR and 13 PR. The median time to progression and the median survival
time in glioblastoma patients were 12.3 months and 17.3 months, respectively. On univariate analysis, histologic grade (P¼0.0001)
and Karnofsky performance status (P¼0.036) had a significant impact on survival, and on multivariate analysis, histologic grade alone
was a significant prognostic factor for survival (P¼0.001). Although grade 4 leukopenia and grade 4 thrombocytopenia occurred in
10 and 7% of all patients, respectively, these were transient with no patients developing neutropenic fever or intracranial
haemorrhage. No serious nonhaematological or late toxicities were seen. These results indicated that radiotherapy delivered
immediately after HBO with chemotherapy was safe with virtually no late toxicity in patients with high-grade gliomas. Further studies
are required to strictly evaluate the effectiveness of radiotherapy after HBO for these tumours.
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High-grade gliomas are relatively uncommon tumours, but cause a
disproportionate number of cancer-related deaths because of their
high lethality (Fine, 1994; Laperriere et al, 2002). Radiotherapy is a
well established treatment for high-grade gliomas and plays an
important role in the overall treatment of such patients, although it
results in only a modest improvement in patient survival (Walker
et al, 1978; Kristiansen et al, 1981). High-grade gliomas are
generally considered to be radioresistant since a high fraction of
tumour cells are hypoxic and resistant to radiotherapy as a result
(Kayama et al, 1991; Rampling et al, 1994; Collingridge et al, 1999).
Several reports have indicated that the median pO2 for high-grade
gliomas studied under anaesthesia was approximately 5–7mmHg
with a significant proportion of observed pO2 values being
o2.5mmHg (Kayama et al, 1991; Collingridge et al, 1999).
Molecular oxygen has long been recognised to be a powerful
modifier of cellular radiation sensitivity. The biological effect of
ionising radiation has been reported to be increased approximately
threefold when irradiation is performed under well-oxygenated
conditions compared to anoxic conditions (Gray et al, 1953).
Hyperbaric oxygenation (HBO) improves the oxygen supply to
hypoxic tumour cells, and offers one approach to overcome
tumour cell hypoxia such that this treatment has been used in
combination with radiotherapy to treat malignant tumours (Jain,
1990; Hartmann et al, 2001). In this context, HBO is using oxygen
as a drug by dissolving it in the plasma and delivering it to the
tissues independent of haemoglobin. In some clinical trials and
recent meta-analyses, significant improvements in both local
tumour control and patient survival have been seen in patients
with cancers of the head and neck and uterine cervix (Henk et al,
1977; Lindegaard et al, 1996; Overgaard and Horsman, 1996).
Nevertheless, the delivery of simultaneous irradiation in combina-
tion with HBO is complex and time-consuming with some trials
noting increased side effects (Jain, 1990; Dische, 1991; Dowling
et al, 1992). As a result, the regimen of HBO in combination with
simultaneous radiotherapy has not been used as a standard
treatment for malignant tumours.
However, recent studies suggest that the oxygen tension within
tumours improves during HBO with the increase being maintained
for minutes following cessation of HBO (Kinoshita et al, 2000,
Kunugita et al, 2001; Beppu et al, 2002). Many investigators have
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sreported that malignant glioma cellular metabolism is anaerobic
with the tumour exhibiting a lower oxygen consumption rate to
normal white matter (Ito et al, 1982; Tyler et al, 1987; Mineura
et al, 1994). The pO2 of normal brain tissue has been noted to
decrease quickly after HBO treatment in animal experiments while
the pO2 in high-grade gliomas falls more slowly after decompres-
sion as a result of the lower rate of oxygen consumption and the
reduced blood flow to the tumour (Jamieson and van den Brenk,
1963). Therefore, in contrast to normal brain tissue, the pO2 within
the tumour may remain elevated for a substantial period of time
after decompression. The resultant increase in the oxygen tension
within tumour cells would be predicted to sensitise high-grade
gliomas to the cytotoxic effects of irradiation (Gray et al, 1953;
Hall, 1994). This hypothesis suggests that radiotherapy immedi-
ately after HBO may increase the sensitivity of hypoxic tumour
cells to radiotherapy without increasing the injury to normal brain
tissue. Recently, several studies have shown the feasibility of this
treatment regimen with HBO applied prior to radiotherapy for
high-grade gliomas (Kohshi et al, 1999; Beppu et al, 2003; Ogawa
et al, 2003). However, there has been little information regarding
the clinical efficacy and safety of this treatment strategy.
In addition to radiotherapy, chemotherapy is often administered
as a peri- or post-radiation treatment for patients with high-grade
gliomas. Although the role of chemotherapy remains controversial,
recent meta-analyses have demonstrated an increase in patient
survival for patients treated with both chemotherapy and radio-
therapy as opposed to those treated with radiotherapy alone (Fine
et al, 1993; Stewart, 2002). Moreover, a recent randomised trial also
demonstrated that the addition of concurrent chemotherapy
(temozolomide) to radiotherapy resulted in a clinically meaningful
and statistically significant survival benefit for patients with newly
diagnosed glioblastoma (Stupp et al, 2005). Therefore, the
standard of care has now shifted from radiotherapy alone to
concurrent chemo/radiotherapy for these tumours.
Based on this background, we conducted a phase II study to
evaluate the efficacy and toxicity of radiotherapy after HBO
together with chemotherapy in adults with high-grade gliomas.
MATERIALS AND METHODS
Patient selection
This study was performed according to the guidelines approved by
the institutional review board of our institution, with written
informed consent being obtained from all patients. Patients
aged 18 years of age or older with a histologically confirmed
supratentorial glioblastoma, anaplastic astrocytoma, anaplastic
oligoastrocytoma or anaplastic oligodendroglioma according to
the World Health Organization (WHO) criteria (2000) who had not
received prior treatment were eligible to take part in the study. All
slides were reviewed by the same neuropathologist at our
institution (SA). Other eligibility criteria included the following:
Karnofsky performance status (KPS) score X50%, normal bone
marrow function (haemoglobin X10gdl
 1, white blood cell
(WBC) count X3000ml
 1, platelet count X100000mm
 3), normal
renal function (serum creatinine o1.2mgdl
 1), normal liver
function (AST o1.5 times normal, bilirubin o1.5mgdl
 1) and no
evidence of cardiopulmonary disease or sinusitis.
Hyperbaric oxygenation
Hyperbaric oxygenation treatment was performed in a multiplace
hyperbaric chamber according to the following schedule: approxi-
mately 18min of compression with air, 30–60min of 100% oxygen
inhalation using an oxygen mask at 2.8. Atmospheres absolute and
approximately 18min of decompression with oxygen inhalation.
Following HBO, each patient was promptly moved to the treatment
room and underwent radiotherapy. The period of time from
completion of decompression to irradiation was consistently
o15min for each treatment fraction. All patients were gowned
in regulation nonflammable pyjamas and no patients received
sedation for each session.
Radiotherapy
Radiotherapy began within 4 weeks of surgical resection. Each
irradiation treatment was administered daily after HBO and was
delivered with megavoltage machines of photon energies X4MeV.
A head-holding device that was transparent to X-rays was used in
order to ensure adequate immobilisation during radiotherapy and
reproducibility. The treatment volume for both the initial volume
and the boost volume was based on the preoperative computed
tomography (CT) or magnetic resonance imaging (MRI) scans,
and CT-guided treatment planning was required. The radiotherapy
schedule consisted of a total dose of 60Gy prescribed at the
International Commission on Units and Measurements (ICRU)
reference point and administered in 30 daily fractions over a
period of 6 weeks (5 fractions per week). For the first 40Gy, the
treatment volume consisted of the contrast-enhancing lesions and
surrounding oedema demonstrated on the CT or MRI scans with a
3cm margin. After 40Gy, the treatment volume was reduced and
included the contrast-enhancing lesion (without oedema) apparent
on the preoperative CT or MRI scans with a 2.5cm margin.
Anticonvulsive drugs, such as phenytoin or zonisamide, were
administered orally to all patients during and after radiotherapy.
Corticosteroids were used perioperatively, during the early phase
of radiotherapy and as necessary thereafter. The corticosteroid
dose had to remain stable for at least 1 week prior to entry into the
study.
Chemotherapy
Initial chemotherapy was administered concurrently with radio-
therapy. One course of chemotherapy consisted of procarbazine
90mgm
 2 orally on days 1–14, nimustine (ACNU) 80mgm
 2
intravenously on day 1 and vincristine 0.5mgm
 2 intravenously
on days 1 and 8. Cycles of chemotherapy were repeated at
approximately 3 monthly intervals after radiotherapy up to a
maximal total of four courses or until the tumour progressed or
until the patient refused to receive further chemotherapy. All
patients received antiemetics with granisetron and metoclopra-
mide before ACNU administration.
Patient evaluations
The extent of surgical resection was determined from the surgical
records and postoperative CT or MRI scans by the neurosurgeons
(YY and SA). Gross total resection represented a complete removal
of the visible tumour, partial resection involved a 5–99% volume
reduction and a biopsy sample indicated a o5% resection. All
patients underwent a complete clinical history and physical
examination, preoperative and postoperative CT and/or MRI
scans, complete blood count (CBC), differential white cell count,
platelet count, chemistry survey, neuropsychological testing and a
chest radiograph before entry into the study. CBC, differential
white cell count and platelet counts were obtained every week
during treatment while a chemistry survey was performed every 2
weeks during treatment. Neurological examination and contrast-
enhanced CT or MRI scans were obtained every 6–8 weeks during
the first year. During the second year, patients in remission were
evaluated with neurological examinations and contrast-enhanced
CT or MRI scans at 3-month intervals. Neuropsychological
assessment was conducted before radiation therapy and every 6
months thereafter or until the patient could no longer be tested.
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Assessment of response was based on postoperative CT or MRI
scans that were obtained before and after radiotherapy and by
neurological examination as described by Macdonald et al (1990).
In brief, complete response (CR) was defined as the complete
disappearance of all visible tumour, no steroid therapy and a
neurologically stable or improved condition. Partial response (PR)
was defined as a X50% reduction in the product of the
perpendicular diameters of the contrast-enhancing tumour in
patients on a stable or decreasing dose of steroids who were
neurologically stable or improved. Progressive disease (PD) was
defined as a 425% increase in the product of the perpendicular
diameters of the contrast-enhancing tumour or any new tumour
seen on CT or MRI scans or neurologically worse, and the steroid
dose being stable or increased. All other situations were defined as
stable disease (SD). On the other hand, patients with no
measurable contrast enhancing disease postoperatively were
deemed to be non-assessable for response determination.
All toxicities were recorded and graded according to the
common toxicity criteria of the National Cancer Institute, version
2.0. The dose of chemotherapy was decreased 33% for a nadir WBC
count 1000–1500ml
 1 or platelet count 20000–50000ml
 1. For a
nadir WBC count o1000ml
 1 or platelet count o20000ml
 1, the
dose of all agents was decreased by 50%. Chemotherapy was
delayed if the WBC count was o3000ml
 1 or the platelet count
o100000ml
 1 at the beginning of each cycle until marrow
recovery had occurred. Radiotherapy was delayed if the WBC
count was o1000ml
 1 or the platelet count o20000ml
 1 until
marrow recovery had occurred. Chemotherapy was delayed if the
AST level was elevated or if the direct bilirubin level was less than
three times normal, until values fell to below twice the upper limit
of normal. Chemotherapy was then restarted at 50% of the initial
dose.
Statistical analysis
Overall survival and progression-free survival rates were calculated
actuarially according to the Kaplan–Meier method (Kaplan and
Meier, 1958) and were measured from the day of surgical resection.
Differences between groups were estimated using the log rank test
(Mantel, 1966). Multivariate analysis was performed using the Cox
regression model (Cox, 1972). A probability level of 0.05 was
chosen for statistical significance. Statistical analysis was per-
formed using the SPSS software package (version 11.0; SPSS Inc.,
Chicago, IL, USA).
RESULTS
Patient characteristics
Forty-one adults with newly diagnosed supratentorial high-grade
gliomas were enrolled onto this trial between January 2000 and
December 2003. The patient characteristics are detailed in Table 1.
All patients were followed through December 2005 or until they
died, and were evaluated for efficacy and toxicity of this treatment.
The median follow-up time in the surviving patients was 57.1
months (range 28.1–70.6 months).
Treatment delivered
All 41 patients completed a total dose of 60Gy radiotherapy
immediately after HBO with one course of concurrent chemo-
therapy. Thirty-three of 41 patients (80%) received further courses
of chemotherapy after radiotherapy. The total courses of chemo-
therapy administered were four courses in 10 patients, three
courses in six patients, two courses in 17 patients, and one course
in eight patients.
Response, survival and prognostic factors
Eleven patients had undergone a gross total resection and had no
evaluable tumour at the initiation of protocol therapy. Therefore,
30 of 41 patients could be evaluated for response within 1 month
after the completion of radiotherapy (glioblastoma: 22 patients,
grade-3 gliomas: eight patients). Of these 30 patients, 17 (57%) had
an objective response including four CR (13%) and 13 PR (43%).
Twelve patients (40%) had SD and one patient experienced PD.
At the time of this analysis, 33 patients died (30 patients with
glioblastoma and three patients with grade 3 tumours) and two
patients with grade 3 tumours were alive with evidence of disease
progression (follow-up, 36.9 and 28.1 months, respectively). The
remaining six patients (one patient with glioblastoma and five
patients with grade 3 tumours) had no evidence of tumour
recurrence or disease progression (median follow-up, 68.2 months;
range, 34.6–70.6 months). The median time to progression and the
Table 1 Patient characteristics
Characteristic No. of patients
Total number of patients 41
Gender
Male 24
Female 17
Age (years)
Median 57
Range 22–73
KPS (%)
Median 80
Range 50–100
Histologic grade
31 0
43 1
Tumour location
Frontal 15
Other 26
Tumour size
p4cm 10
44cm 31
Mental status
Normal 35
Abnormal 6
Radiation from symptom
p3 months 22
43 months 19
Neurologic function
Work 21
Other 20
Histology
GM 31
AA 4
AO 6
Extent of resection
Gross total 11
Partial 24
Biopsy 6
AA¼anaplastic astrocytoma; AO¼anaplastic oligodendroglioma; GM¼glioblasto-
ma; KPS¼arnofsky performance status.
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and 17.3 months, respectively. The 2-year actuarial progression-
free survival and the 2-year actuarial overall survival rates in
glioblastoma patients were 10 and 23%, respectively.
Table 2 indicates the results of univariate and multivariate
analyses of potential prognostic factors on survival. On univariate
analysis, histologic grade (P¼0.0001) and Karnofsky performance
status (P¼0.036) had a significant impact on survival, and on
multivariate analysis, histologic grade alone was a significant
prognostic factor for survival (P¼0.001).
Toxicity
During HBO treatment, seven of 41 (17%) patients suffered middle
ear barotrauma requiring tympanostomy with tube placement.
Five of 41 (12%) patients had complaints of nausea requiring
metoclopramide before each HBO treatment. No patients suffered
convulsions during or after HBO.
The major acute toxic effects of chemotherapy (Xgrade 3)
represent the most severe toxicity associated with the study
treatment for each patient (Table 3). The percentage of grade 3–4
leukopenia, anaemia and thrombocytopenia were 44, 5 and 48%,
respectively, with three patients (7%) requiring platelet transfu-
sions and one patient (2%) requiring blood cell transfusions.
Although grade 4 leukopenia and grade 4 thrombocytopenia
occurred in 10 and 7% of all patients, respectively, these were
transient with no patients developing a neutropenic fever or
intracranial haemorrhage. Grade 3 nausea occurred in three
patients (7%). Three patients (7%) developed grade 3 liver
dysfunction and were treated conservatively. No other grade 3 or
more severe nonhaematological toxicities were observed in the
remaining patients. No severe late toxicities, such as intracranial
haemorrhage and mental deterioration, were evident in the
surviving patients at the time of analysis.
All patients exhibited alopecia within the treatment field.
Regrowth of hair occurred over a time period of 4–8 months
from the end of irradiation. Localised scalp erythema was seen in
all patients although no patient experienced moist desquamation.
Comparison of survival according to RPA criteria
We analysed our patients according to the recursive partitioning
analysis (RPA) prognostic factors (Curren et al, 1993), which are
based on a large Radiation Therapy Oncology Group (RTOG)
database of patients with high-grade gliomas (Scott et al, 1998).
Each RPA III, IV and V group in the current study had longer
median survival time and higher 2-year survival than those of
RTOG 90-06 results reported from Scott et al (Table 4).
DISCUSSION
In recent years, radiotherapy immediately after HBO has been
emerging as an attractive approach for overcoming hypoxia in
cancer treatment (Al-Waili et al, 2005; Bennett et al, 2005; Mayer
et al, 2005). Several experimental studies have indicated that the
elevation in oxygen tension in the tumour is preserved for some
time following HBO treatment, thereby allowing the administra-
tion of radiotherapy with an improved tumour/normal tissue
oxygenation ratio (Kinoshita et al, 2000; Kunugita et al, 2001;
Beppu et al, 2002). Using noninvasive MRI, Kinoshita et al (2000)
demonstrated that the signal change related to the oxygen tension
in SCCVII tumours decreased gradually but fell rapidly in muscle
after HBO. Beppu et al (2002) conducted a direct stereotactic
measurement of pO2 in glioblastoma tissue of patients under
various conditions. The pO2 levels were significantly increased in
both peritumoral and intratumoral tissues after HBO with a high
pO2 level being maintained until 15min after HBO in both regions.
Moreover, performing radiotherapy immediately after HBO had a
significant effect in experimental studies. Kunugita et al (2001)
examined the effect of radiotherapy after HBO in SCCVII tumours
(radiobiological hypoxic fraction: approximately 10%) subcuta-
neously transplanted into C3H/He mice using a growth delay
assay. They noted a significant SCCVII tumour growth delay in the
treated animals within 30min after HBO with the tumour growth
delay time being 1.61 times longer than that following radiotherapy
alone. Moreover, oxygenation using HBO also enhanced the
sensitivity to chemotherapy, because the hypoxic conditions
prevalent in the tissue compromised the chemotherapeutic
potential of almost all agents (Rampling et al, 1994; Al-Waili
et al, 2005).
The current study suggested that radiotherapy administered
immediately after HBO with chemotherapy may be promising for
high-grade gliomas. Moreover, the administration of radiotherapy
after HBO enabled the application of conventional fractionation of
radiotherapy and the combination of modern radiotherapy
Table 2 Univariate and multivariate analysis of various potential prognostic factors in patients with high-grade gliomas
P-value
Variable Univariate Multivariate RR (95% CI)
Histologic grade (grade 3 vs grade 4) 0.0001 0.001 0.133 (0.038–0.460)
KPS (o70 vs X70%) 0.037 0.336 0.698 (0.336–1.451)
Neurologic function (vork vs other) 0.138 — —
Tumour location (frontal vs others) 0.187 — —
RT from symptom (p3 vs 43 M) 0.452 — —
Age (o50 vs X50 years) 0.503 — —
Mental status (normal vs abnormal) 0.528 — —
Gender (female vs male) 0.670 — —
Extent of resection (GT, PT vs BT) 0.622 — —
Tumour size (p4 vs 44cm) 0.909 — —
BT¼biopsy; CI¼confidence intervals; GT¼gross total resection; KPS¼Karnofsky performance status; M¼months; PT¼partial resection; RR¼relative risk.
Table 3 Major toxicities (n¼41)
Grade 3 Grade 4
No. % No. %
Leukocytes 14 34 4 10
Haemoglobin 2 5 0 0
Platelets 17 41 3 7
Nausea 3 7 0 0
Hepatic toxicity 3 7 0 0
Radiotherapy after HBO for high-grade gliomas
K Ogawa et al
865
British Journal of Cancer (2006) 95(7), 862–868 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stechniques including patient fixation and three-dimensional
conformal therapy. Several reports have also indicated the
antitumour activity of irradiation immediately after HBO in
conventionally fractionated irradiation (Kohshi et al, 1999; Beppu
et al, 2003). Kohshi et al (1999) applied radiotherapy after HBO to
high-grade glioma patients with residual disease. A total dose of
50–71Gy in 20–30 fractions was administered, and 11 of 15
patients (73%) treated with radiotherapy immediately after HBO
exhibited 450% tumour reduction. The median survivals in
patients with and without HBO were 24 and 12 months,
respectively, and were significantly different (Po0.05). Beppu
et al (2003) applied radiotherapy after HBO with ACNU and
interferon-beta for high-grade gliomas and 50% of glioblastoma
patients exhibited 450% tumour reduction. The current study
also indicated antitumour activity of conventionally fractionated
radiotherapy delivered immediately after HBO with a total dose of
60Gy in 30 fractions. In the 30 patients in whom it was possible to
evaluate the therapeutic response (glioblastoma: 22 patients, grade
3 gliomas: eight patients), 17 (57%) had an objective response
including four CR (17%) and 13 PR (43%). The median survival
time has been reported to be 11–15 months in several phase
studies for glioblastoma (Lassen et al, 1999; Choi et al, 2002; Wick
et al, 2002; Grossman et al, 2003), and was 17.3 months in the
current study. When using RPA analysis criteria, we found that the
median survival times and 2-year survival rates of RPA III, IV and
V classes in the current study compared favourably with patients
in the RTOG databases who were treated in a randomised trial in
the early 1990s (Table 4).
However, these favourable results demonstrated in the current
study should be interpreted with caution. First, the patient
characteristics were generally favourable with 25% of patients
undergoing gross total resection, and 25% of patients having grade
3 gliomas. The median age of 57 was relatively young and the
median KPS of 80 indicated a group with good performance status.
Therefore, one might expect the outcome in this group to be better
than the average described in the literature for glioblastoma.
Second, there is an important difference between the current study
and other previous reports (mostly using adjuvant chemotherapy)
as patients have received concurrent chemotherapy. Comparisons
of the recent results with patients receiving concurrent temozo-
lomide in the Stupp trial (Stupp et al, 2005) indicate that the 2-year
survival rates for glioblastoma are much the same: 23% in the
current study and 26.5% in the Stupp trial. Therefore, it is
necessary to strictly evaluate the true effectiveness of radiotherapy
after HBO for these tumours in further studies.
The current study also indicated that the administration of
radiotherapy immediately after HBO was a safe and practical
procedure. With the routine use of anticonvulsive drugs and
tympanostomy with tube placement in case of middle ear
barotrauma, all 41 patients were able to complete a total dose of
60Gy radiotherapy with conventional fractionation delivered
immediately after HBO. With regard to chemotherapy, all 41
patients could receive one course of concurrent chemotherapy,
and 33 of 41 (80%) patients received further chemotherapies.
Whereas the spectrum of the nonhaematological toxicity was
unremarkable, we observed frequent haematological toxicity with
grade 3 and 4 leukopenia and thrombocytopenia (48% of all
patients). One of the reasons may be the concurrent administra-
tion of chemotherapy and radiotherapy in this protocol (Kleinberg
et al, 1999). However, the incidence of grade 4 haematological
toxicity was less common and was transient. No patients exhibited
neutropenic fever or intracranial haemorrhage and no serious late
toxicity was evident at the time of this analysis. Several authors
have also used a multidrug chemotherapy regimen containing
ACNU, and they also found that grade 3–4 haematological toxicity
was frequent, but of short duration with very few treatment-related
deaths (Choi et al, 2002; Weller et al, 2003). These results indicated
that the administration of radiotherapy immediately after HBO
with chemotherapy was safe and practical with virtually no late
toxicity for high-grade gliomas.
Regarding prognostic factors, many studies have reported that
age, KPS, tumour size, histologic grade and the extent of surgical
resection significantly affect the overall survival for high-grade
gliomas (Laperriere et al, 2002; Buckner, 2003). However, the
current study found no significant differences in overall survival
with respect to age, KPS and extent of surgical resection on
multivariate analysis, and only histologic grade was a significant
prognostic factor for survival. The lack of any significant
differences on survival according to age, KPS and extent of
surgical resection may be the result of the small number of patients
in the current study. Another possible reason, however, may be the
improved radiosensitivity by HBO to large residual tumours as
well as small residual tumours. A close association may exist
between KPS, tumour size, and the extent of surgical resection
because the residual tumour size determined by the operation type
sometimes affects KPS (Beppu et al, 2003). Improvement in the
radiosensitivity of large residual tumours may contribute to an
increased response rate and overall survival for patients with low
KPS and/or large residual tumours. Beppu et al (2003) also found
no significant differences in the response rates with regard to age,
KPS, and extent of surgical resection for high-grade gliomas
treated with radiotherapy immediately after HBO. They concluded
that radiotherapy after HBO could be applied to patients with poor
prognostic factors and resulted in tumour response identical to
patients with good prognostic factors. Further studies are required
to determine which high-grade glioma patients might effectively
benefit from radiotherapy delivered immediately after HBO for
high-grade glioma patients.
Table 4 Comparison of survival according to recursive partitioning analysis criteria
Current study RTOG 90-06
a
No. of patients
b Median survival (months) 2-year survival (%) No. of patients Median survival (months) 2-year survival (%)
RPA class
III 15 23.2 47 105 17.5 30
95% CI 12.0–34.4 21–73 15.6–20.2 21–39
IV 8 20.4 38 240 11.5 17
95% CI 15.1–25.7 4–72 10.8–12.7 11–22
V 15 12.6 20 150 7.4 8
95% CI 9.9–18.5 0–40 6.2–9.1 3–12
CI¼confidence intervals; RPA¼recursive partitioning analysis.
aData from Scott et al, 1998.
bOne patient of RPA class I, one patient with class II and one patient RPA class VI
were not reported.
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sIn conclusion, performing radiotherapy immediately
after HBO with chemotherapy was safe with virtually no late
toxicity for high-grade gliomas. This treatment strategy
may be promising and merits further investigation. Further
prospective randomised trials are also warranted to accurately
determine whether the delivery of radiotherapy immediately
after HBO could be beneficial for patients with high-grade
gliomas.
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